Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB)

CUSIP: 034569103

Q4 2024 13F Holders as of 31 Dec 2024

Type / Class
Equity / Common Stock
Shares outstanding
41,587,315
Total 13F shares
22,570,347
Share change
+15,226,613
Total reported value
$37,311,560
Price per share
$1.68
Number of holders
15
Value change
+$24,974,043
Number of buys
8
Number of sells
4

Quarterly Holders Quick Answers

What is CUSIP 034569103?
CUSIP 034569103 identifies ANEB - Anebulo Pharmaceuticals, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of ANEB - Anebulo Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
22NW, LP
13F
Company
13%
5,366,290
$10,356,940 30 Sep 2024
13F
MANGROVE PARTNERS IM, LLC
13D/G
6.2%
2,525,252
$2,979,797 $0 31 Dec 2024
LVW Advisors, LLC
13F
Company
1.5%
641,039
$1,237,206 30 Sep 2024
13F
Nantahala Capital Management, LLC
13F
Company
1.2%
511,073
$986,371 30 Sep 2024
13F
MORGAN STANLEY
13F
Company
0.96%
399,219
$770,493 30 Sep 2024
13F
Ikarian Capital, LLC
13F
Company
0.38%
157,862
$304,675 30 Sep 2024
13F
VANGUARD GROUP INC
13F
Company
0.37%
154,036
$297,289 30 Sep 2024
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.21%
87,790
$169,474 30 Sep 2024
13F
BOOTHBAY FUND MANAGEMENT, LLC
13F
Company
0.05%
18,978
$36,628 30 Sep 2024
13F
BlackRock, Inc.
13F
Company
0.01%
3,905
$7,536 30 Sep 2024
13F
Tower Research Capital LLC (TRC)
13F
Company
0.01%
2,694
$5,199 30 Sep 2024
13F
UBS Group AG
13F
Company
0%
763
$1,473 30 Sep 2024
13F
BANK OF AMERICA CORP /DE/
13F
Company
0%
76
$147 30 Sep 2024
13F
JPMORGAN CHASE & CO
13F
Company
0%
9
$17 30 Sep 2024
13F
Simon Allen
3/4/5
Chief Executive Officer, Director
class O/S missing
70,246
09 Dec 2022
Karah Herdman Parschauer
3/4/5
Director
class O/S missing
30,425
21 Apr 2022

Institutional Holders of Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) as of Q4 2024

As of 31 Dec 2024, Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) was held by 15 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 22,570,347 shares. The largest 10 holders included 22NW, LP, Nantahala Capital Management, LLC, MANGROVE PARTNERS IM, LLC, LVW Advisors, LLC, MORGAN STANLEY, Ikarian Capital, LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, KING LUTHER CAPITAL MANAGEMENT CORP, and BOOTHBAY FUND MANAGEMENT, LLC. This page lists 15 institutional shareholders reporting positions in this security for the Q4 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q4 2024 vs Q3 2024 Across Filers

Q3 2024 holders
13
Q4 2024 holders
15
Holder diff
2
Investor Q3 2024 Shares Q4 2024 Shares Share Diff Share Chg % Q3 2024 Value $ Q4 2024 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .